| Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices |
Strategic Insights |
September 2023 |
| Formulary assessment – Glucagon (Ogluo) |
Formulary assessment tools |
October 2022 |
| Comparison of DPP-4 inhibitors (Gliptins) |
Prescriber Support Tools |
October 2022 |
| Formulary assessment – estradiol/progesterone (Bijuve) for HRT |
Formulary assessment tools |
May 2022 |
| Estradiol / progesterone (Bijuve®) for hormone replacement therapy in postmenopausal women |
New Drug Evaluations |
May 2022 |
| Formulary assessment – estradiol spray (Lenzetto) |
Formulary assessment tools |
May 2022 |
| Formulary assessment – testosterone 2% gel (Tostran) in post-menopausal women |
Formulary assessment tools |
May 2022 |
| Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart |
Evaluation report |
March 2022 |
| Estradiol spray for the treatment of menopausal symptoms |
New Drug Evaluations |
February 2022 |
| Drugs affecting bone metabolism |
Prescribing Data Report |
August 2021 |
